| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Umar Nishan, Nighat Jabeen, Amir Badshah, Nawshad Muhammad, Mohibullah Shah, Irfan Ullah, Saifullah Afridi, Jibran Iqbal, Muhammad Asad, Riaz Ullah, Essam A Ali, Sarfraz Ahmed, Suvash Chandra Ojh. Nanozyme-based sensing of dopamine using cobalt-doped hydroxyapatite nanocomposite from waste bones. Frontiers in bioengineering and biotechnology. vol 12. 2024-05-02. PMID:38694624. |
however, the abnormal levels of dopamine mainly point to parkinson's, alzheimer's, cardiovascular diseases, etc. |
2024-05-02 |
2024-05-04 |
Not clear |
| Hyun-Ju Lee, JinHan Nam, Jeong-Woo Hwang, Jin-Hee Park, Yoo Joo Jeong, Ji-Yeong Jang, Su-Jeong Kim, A-Ran Jo, Hyang-Sook Ho. L-DOPA regulates neuroinflammation and Aβ pathology through NEP and ADAM17 in a mouse model of AD. Molecular brain. vol 17. issue 1. 2024-04-30. PMID:38685105. |
dopamine plays important roles in cognitive function and inflammation and therefore is involved in the pathogenesis of neurodegenerative diseases, including alzheimer's disease (ad). |
2024-04-30 |
2024-05-03 |
mouse |
| J Sonia, B N Kumara, Kevin Joakim Pinto, A Hashim, E S Sindhu Priya, B Kalpana, Renjtih Thomas, K Sudhakara Prasa. Disposable paper electrodes for detection of changes in dopamine concentrations in rat brain homogenates. Talanta. vol 274. 2024-03-27. PMID:38537354. |
the abnormal dopamine levels can result in neurological disorders such as parkinson's, alzheimer's, schizophrenia, acute anxiety, neuroblastoma and also contribute to cognitive dysfunctions. |
2024-03-27 |
2024-03-30 |
rat |
| Anna B Szabo, Farès Sayegh, Sèbastien Gauzin, Camille Lejards, Bruno Guiard, Luc Valton, Laure Verret, Claire Rampon, Lionel Daha. No major effect of dopamine receptor 1/5 antagonist SCH-23390 on epileptic activity in the Tg2576 mouse model of amyloidosis. The European journal of neuroscience. 2024-02-03. PMID:38308520. |
here, we tested the implication of dopaminergic transmission in vivo in the tg2576 mouse model of alzheimer's disease by monitoring epileptic activities via intracranial eeg before and after treatment with dopamine antagonists. |
2024-02-03 |
2024-02-05 |
mouse |
| Anna B Szabo, Farès Sayegh, Sèbastien Gauzin, Camille Lejards, Bruno Guiard, Luc Valton, Laure Verret, Claire Rampon, Lionel Daha. No major effect of dopamine receptor 1/5 antagonist SCH-23390 on epileptic activity in the Tg2576 mouse model of amyloidosis. The European journal of neuroscience. 2024-02-03. PMID:38308520. |
while requiring further investigation, our results indicate that on a systemic level, dopamine receptors are not significantly contributing to epilepsy observed in vivo in this mouse model of alzheimer's disease. |
2024-02-03 |
2024-02-05 |
mouse |
| Elena Spoleti, Livia La Barbera, Emma Cauzzi, Maria Luisa De Paolis, Luana Saba, Ramona Marino, Giuseppe Sciamanna, Vincenzo Di Lazzaro, Flavio Keller, Annalisa Nobili, Paraskevi Krashia, Marcello D'Ameli. Dopamine neuron degeneration in the Ventral Tegmental Area causes hippocampal hyperexcitability in experimental Alzheimer's Disease. Molecular psychiatry. 2024-01-16. PMID:38228889. |
dopamine neuron degeneration in the ventral tegmental area causes hippocampal hyperexcitability in experimental alzheimer's disease. |
2024-01-16 |
2024-01-19 |
mouse |
| Ammara Shaikh, Fairus Ahmad, Seong Lin Teoh, Jaya Kumar, Mohamad Fairuz Yahay. Targeting dopamine transporter to ameliorate cognitive deficits in Alzheimer's disease. Frontiers in cellular neuroscience. vol 17. 2023-12-01. PMID:38026688. |
targeting dopamine transporter to ameliorate cognitive deficits in alzheimer's disease. |
2023-12-01 |
2023-12-10 |
Not clear |
| Sungwoo Kang, Seun Jeon, Young-Gun Lee, Byoung Seok Y. Dopamine transporter positron emission tomography in patients with Alzheimer's disease with Lewy body disease features. Neurobiology of aging. vol 134. 2023-11-22. PMID:37992545. |
dopamine transporter positron emission tomography in patients with alzheimer's disease with lewy body disease features. |
2023-11-22 |
2023-11-29 |
Not clear |
| Namitha R, Manasa Kh, Santhosh N Hegde, Noorunnisa Begum, Subrahmanya Kumar Kukkupuni, Malali Gowda, Pavithra Narendra. De novo genome assembly and annotation of the medicinal plant Tinospora cordifolia (Willd.) Miers ex Hook. f. & Thom's. Functional & integrative genomics. vol 23. issue 4. 2023-11-07. PMID:37935874. |
in comparison to the standard drug (dopamine, rasagiline, and selegiline), syringin's molecular docking exhibited a greater binding affinity from the range of - 4.3 to - 6.6 kcal/mol for all the targets of parkinson's disease and for alzheimer's targets; it has shown the maximum potency from the range of - 6.5 to - 7.4 kcal/mol with respect to the standard drug (donepezil, galantamine, and rivastigmine). |
2023-11-07 |
2023-11-20 |
Not clear |
| Iman Touati, Mohnad Abdalla, Yassir Boulaamane, Nawal Al-Hoshani, Abdulaziz Alouffi, Mohammed Reda Britel, Amal Maurad. Identification of novel dual acting ligands targeting the adenosine A2A and serotonin 5-HT1A receptors. Journal of biomolecular structure & dynamics. 2023-10-18. PMID:37850444. |
pd is the second most ubiquitous neurological disorder after alzheimer's disease, characterized by the depletion of dopamine in the central nervous system due to the impairment of dopaminergic neurons, leading to involuntary movements or dyskinesia. |
2023-10-18 |
2023-11-08 |
Not clear |
| Yangjing Lv, Zhiyuan Zheng, Renzheng Liu, Jianan Guo, Changjun Zhang, Yuanyuan Xi. Monoamine oxidase B inhibitors based on natural privileged scaffolds: A review of systematically structural modification. International journal of biological macromolecules. 2023-08-07. PMID:37549764. |
overexpression of mao-b and insufficient dopamine concentration are recognized as pathological factors in neurodegenerative diseases (nds) including parkinson's disease (pd) and alzheimer's disease (ad). |
2023-08-07 |
2023-08-14 |
Not clear |
| Sungwoo Kang, Seun Jeon, Young-Gun Lee, Byoung Seok Y. Striatal Dopamine Transporter Uptake, Parkinsonism, and Cognition in Alzheimer's Disease. European journal of neurology. 2023-07-26. PMID:37493955. |
striatal dopamine transporter uptake, parkinsonism, and cognition in alzheimer's disease. |
2023-07-26 |
2023-08-14 |
Not clear |
| Athulya Krishna, Sunil Kumar, Sachithra Thazhathuveedu Sudevan, Ashutosh Kumar Singh, Leena K Pappachen, T M Rangarajan, Mohamed A Abdelgawad, Bijo Mathe. A comprehensive review of the docking studies of chalcone for the development of selective MAO-B inhibitors. CNS & neurological disorders drug targets. 2023-05-16. PMID:37190818. |
monoamine oxidase b is a crucial therapeutic target for neurodegenerative disorders like alzheimer's and parkinson's since they assist in disintegrating neurotransmitters such as dopamine in the brain. |
2023-05-16 |
2023-08-14 |
Not clear |
| Teresa Juárez-Cedillo, Nancy Martínez-Rodríguez, José Manuel Fragoso, Valentin Islas-Pérez, Amara López-Martínez, Antonio Valle-Medin. Multifactor Dimensionality Reduction Analysis to Evaluate the Association of Dopamine Beta-Hydroxylase (DΒH) Polymorphisms with Susceptibility to Dementia (SADEM Study). Molecular neurobiology. 2023-05-06. PMID:37148523. |
since the activity of dopamine b hydroxylase (dβh) is reduced in the hippocampus and neocortex in the brain, changes in the physiological status of dopamine have been reported in alzheimer's disease (ad) induced by this enzyme. |
2023-05-06 |
2023-08-14 |
Not clear |
| Yongheum Choi, Chang Su Jeon, Kwang Bok Kim, Hyun-Jong Kim, Sung Hyun Pyun, Young Min Par. Quantitative detection of dopamine in human serum with surface-enhanced Raman scattering (SERS) of constrained vibrational mode. Talanta. vol 260. 2023-05-05. PMID:37146455. |
dopamine (da) is a crucial neurotransmitter involved in the hormonal, nervous, and vascular systems being considered as an index to diagnose neurodegenerative diseases, including parkinson's and alzheimer's disease. |
2023-05-05 |
2023-08-14 |
human |
| Anaí Laurel Leon, Nicolas Alejandro Sacco, Fernanda Miranda Zoppas, Rosario Galindo, Emilio Muñoz Sandoval, Fernanda Albana Marchesin. Dopamine removal from water by advanced oxidative processes with Fe/N-doped carbon nanotubes. Environmental science and pollution research international. 2023-03-09. PMID:36892703. |
dopamine (da) is an important neurotransmitter in the human body, and a subnormal level is associated with some neurological problems, such as alzheimer's and parkinson's diseases. |
2023-03-09 |
2023-08-14 |
human |
| Waijiao Cai, Kazumasa Wakamatsu, Fabio A Zucca, Qing Wang, Kai Yang, Niyaz Mohamadzadehonarvar, Pranay Srivastava, Hitomi Tanaka, Gabriel Holly, Luigi Casella, Shosuke Ito, Luigi Zecca, Xiqun Che. DOPA pheomelanin is increased in nigral neuromelanin of Parkinson's disease. Progress in neurobiology. 2023-02-06. PMID:36746222. |
using postmortem sn from patients with pd or alzheimer's disease (ad) and unaffected controls, we identified increased l-3,4-dihydroxyphenylalanine (dopa) pheomelanin and increased ratios of dopamine (da) pheomelanin markers to da in pd sn compared to controls. |
2023-02-06 |
2023-08-14 |
human |
| Riccardo Camedda, Chiara Giuseppina Bonomi, Martina Gaia Di Donna, Agostino Chiaravallot. Functional Correlates of Striatal Dopamine Transporter Cerebrospinal Fluid Levels in Alzheimer's Disease: A Preliminary International journal of molecular sciences. vol 24. issue 1. 2023-01-08. PMID:36614193. |
functional correlates of striatal dopamine transporter cerebrospinal fluid levels in alzheimer's disease: a preliminary the aim of our study was to investigate regional glucose metabolism with 18f-fdg positron emission tomography/computed tomography in a population of patients with alzheimer's disease (ad) in relation to cerebrospinal (csf) levels of striatal dopamine transporter (dat). |
2023-01-08 |
2023-08-14 |
Not clear |
| Xin Liu, Zhao-Yan Cheng, Yan-Feng Li, Chao Liu, Chen Wang, Gong Xiao-Jian, Ling H. Dopamine D2 receptor agonist Bromocriptine ameliorates Aβ European journal of pharmacology. 2022-12-05. PMID:36470446. |
dopamine d2 receptor agonist bromocriptine ameliorates aβ alzheimer's disease (ad) is the most common neurodegenerative disease, which lacks disease-modifying therapeutics so far. |
2022-12-05 |
2023-08-14 |
Not clear |
| Livia La Barbera, Annalisa Nobili, Emma Cauzzi, Ilaria Paoletti, Mauro Federici, Luana Saba, Cecilia Giacomet, Ramona Marino, Paraskevi Krashia, Marcello Melone, Flavio Keller, Nicola Biagio Mercuri, Maria Teresa Viscomi, Fiorenzo Conti, Marcello D'Ameli. Upregulation of Ca Molecular neurodegeneration. vol 17. issue 1. 2022-11-26. PMID:36434727. |
upregulation of ca recent clinical and experimental studies have highlighted the involvement of ventral tegmental area (vta) dopamine (da) neurons for the early pathogenesis of alzheimer's disease (ad). |
2022-11-26 |
2023-08-14 |
mouse |